Glioblastoma is the most common malignant primary brain tumor in adults. Its often rapid
clinical course, with many medical and psychosocial challenges, requires a multidisciplinary …

Glioblastoma multiforme (GBM) is commonly known as the most aggressive primary CNS
tumor in adults. The mean survival of it is 14 to 15 months, following the standard therapy …

Background Treatment options for recurrent glioblastoma are scarce, with second-line
chemotherapy showing only modest activity against the tumour. Despite the absence of well …

Purpose Bevacizumab (BEV) is approved in more than 60 countries for use in adults with
recurrent glioblastoma. We evaluated the addition of BEV to radiotherapy plus …

Despite treatment with the current standard-of-care therapies, patients with newly diagnosed
glioblastoma multiforme (GBM) exhibit dismal prognoses. Bevacizumab has demonstrated …

Glioblastoma is characterized by high expression levels of proangiogenic cytokines and
microvascular proliferation, highlighting the potential value of treatments targeting …

Background Cabozantinib is a tyrosine kinase inhibitor with activity against vascular
endothelial growth factor receptor 2 (VEGFR2) and MET that has demonstrated clinical …

Purpose: Preclinical studies have demonstrated that postirradiation tumor revascularization
is dependent on a stromal cell–derived factor-1 (SDF-1)/CXC chemokine receptor type 4 …

Background Amide proton transfer (APT) MRI has the potential to demonstrate antitumor
effects by reflecting biologically active tumor portion, providing different information from …

Despite advances in upfront therapy, the prognosis in the great majority of patients with
glioblastoma (GBM) is poor as almost all recur and result in disease-related death …